Stocks to Buy: A new listing has become Jefferies' latest 'high
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Jefferies initiated coverage on Molbio Diagnostics with a buy rating on September 30, calling it a high-conviction top pick.
- ✓The bank set a price target of ₹1,600, suggesting a 27% upside.
- ✓Jefferies said, "With multiple other products under development, we believe Molbio's innovation pipeline extends well beyond its flagship product."
Story at a Glance
- Category
- BUSINESS
- Reported By
- CNBC TV18
- Reading Speed
- 3 Minute(s)
- Market Focus
- India Economy
Stocks to Buy: A new listing has become Jefferies' latest 'high-conviction top pick'; Check upside targets
Molbio Diagnostics has successfully commercialized a differentiated point-of-care molecular diagnostics platform, Jefferies wrote in its note, adding that with two emerging platforms and a robust product pipeline ahead, the company is well-positioned for strong growth ahead.
By Hormaz Fatakia
Global investment bank Jefferies has initiated coverage on recently listed Molbio Diagnostics Ltd. with a "buy" rating, calling it a "high-conviction top pick".
In its note on Wednesday, September 30, Jefferies ascribed a price target of ₹1,600 for Molbio Diagnostics, which implied an upside potential of 27% from current levels.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
CNBC TV18
Read the full, original unfiltered story directly on the publisher's portal.